{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T16:30:09Z","timestamp":1722011409759},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/crd.0000000000000075","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T10:49:11Z","timestamp":1430304551000},"page":"261-267","source":"Crossref","is-referenced-by-count":8,"title":["Vorapaxar"],"prefix":"10.1097","volume":"23","author":[{"given":"Sum","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis.","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"R2-7-20210203","first-page":"e28","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics2014 update: a report from the American Heart Association.","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.","volume":"348","author":"Gent","year":"1996","journal-title":"Lancet"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.cir.0000442015.53336.12","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics2014 update: a report from the American Heart Association.","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/clc.22233","article-title":"New antithrombotics for secondary prevention of acute coronary syndrome.","volume":"37","author":"Goto","year":"2014","journal-title":"Clin Cardiol"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ddr.10304","article-title":"Design and evaluation of potent peptide-mimetic PAR1 antagonists.","volume":"59","author":"Derian","year":"2003","journal-title":"Drug Develop Res"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/hh1001.091447","article-title":"New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology.","volume":"88","author":"Patterson","year":"2001","journal-title":"Circ Res"},{"issue":"suppl 1","key":"R12-7-20210203","first-page":"55","article-title":"Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects.","volume":"83","author":"Kosoglou","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/cpdd.30","article-title":"Effect of food, antacid, and age on the pharmacokinetics of the oral thrombin receptor antagonist vorapaxar (sch 530348) in healthy volunteers.","volume":"2","author":"Kosoglou","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpdd.38","article-title":"The absence of a clinically significant effect of food on the single dose pharmacokinetics of Vorapaxar, a PAR-1 antagonist, in healthy adult subjects.","volume":"2","author":"Behm","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-011-1127-z","article-title":"No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-7-20210203","first-page":"S54","article-title":"Pharmacokinetics of vorapaxar and its metabolite sch 2046273 (M20) following oral administration in healthy Chinese and US subjects.","volume":"91","author":"Statkevich","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cpdd.49","article-title":"Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QTQTc interval in healthy volunteers: a randomized, placebo- and positive-controlled, parallel group trial.","volume":"3","author":"Kosoglou","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH13-07-0624","article-title":"Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.","volume":"111","author":"Storey","year":"2014","journal-title":"Thromb Haemost"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events.","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"TRA 2P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial.","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Steering Committee and Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"R24-7-20210203","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic EventsTIMI 50 Trial.","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcph.20","article-title":"The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.","volume":"53","author":"Kosoglou","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cpdd.11","article-title":"The influence of multiple-dose vorapaxar, an oral PAR-1 receptor antagonist, on the single-dose pharmacokinetics and pharmacodynamics of digoxin.","volume":"2","author":"Kosoglou","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R28-7-20210203","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00228-012-1271-0","article-title":"Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R29-7-20210203","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00228-012-1269-7","article-title":"Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.","volume":"68","author":"Statkevich","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-7-20210203","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-012-1217-6","article-title":"Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:48Z","timestamp":1620949788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201509000-00007"}},"subtitle":["A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000075","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}